Oslo, 31 May 2024 - Observe Medical ASA ("the Company" or "Observe Medical")
announces that its subsidiary, Biim AS ("Biim"), has extended its agreement with
Fresenius Medical Care ("Fresenius") for the supply of wireless pocketable
ultrasound devices.

The initial agreement with Fresenius was entered into in October 2021, with a
one-year extension exercised in October 2023. This renewal extends the
partnership for an additional two years, until April 1, 2026.

Under the agreement, Biim will continue to supply Fresenius with their wireless
pocketable ultrasound devices for use in their dialysis clinics across the
United States. As of today, Biim has successfully delivered 285 units in select
Fresenius test clinics, positioning the Company for potential expansion to all
approx. 3,000 US clinics.

This renewal strengthens Biim's position within the dialysis market and
demonstrates continued confidence from a leading global healthcare provider like
Fresenius.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.